Production (Stage)
Innate Pharma S.A.
IPHA
$2.08
-$0.09-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.04% | -46.68% | |||
| Total Other Revenue | -3.04% | -13.11% | |||
| Total Revenue | -3.04% | -35.66% | |||
| Cost of Revenue | -3.04% | -19.54% | |||
| Gross Profit | 3.04% | 7.65% | |||
| SG&A Expenses | -3.04% | 8.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.04% | -12.71% | |||
| Operating Income | 3.04% | 1.94% | |||
| Income Before Tax | 3.04% | -1.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.04% | -1.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.04% | -1.91% | |||
| EBIT | 3.04% | 1.94% | |||
| EBITDA | 3.04% | 1.26% | |||
| EPS Basic | 3.05% | -1.46% | |||
| Normalized Basic EPS | 3.06% | -1.46% | |||
| EPS Diluted | 3.05% | -0.24% | |||
| Normalized Diluted EPS | 3.06% | -1.46% | |||
| Average Basic Shares Outstanding | 0.00% | 0.44% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||